Appointments
Bruker Adds Diagnostics Leader Jack Phillips to Board of Directors Effective January 2026
Bruker Corporation; Jack Phillips; Board of Directors; appointment; January 1 2026; diagnostics industry; corporate governance; Accelerate Diagnostics; Roche Diagnostics North America; Ventana Medical Systems
Vera Therapeutics Appoints James R. Meyers to Its Board of Directors
Vera Therapeutics; James R. Meyers; Board of Directors; appointment; biotech executive; IgA nephropathy; atacicept; autoimmune diseases; Gilead Sciences; IntraBio Ltd; biopharmaceutical
Zentek Appoints Mohammed Jiwan as CEO
Zentek; Mohammed Jiwan; CEO appointment; ZenGUARD; nanomaterials; graphene; technology; commercialization
ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy
ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology
Inspira Technologies Appoints Former Johnson & Johnson Executive as VP of Global Sales
Inspira Technologies; Mike Hershkovitz; Johnson & Johnson; VP of Global Sales; leadership appointment; healthcare; commercialization; board of directors
Epiminder Appoints Mark McLellan as Chief Financial Officer
Epiminder; Mark McLellan; CFO appointment; epilepsy monitoring; Minder system; FDA authorization; healthcare finance; medical device company
Solventum Appoints Heather Knight as Chief Commercial Officer
Solventum; Heather Knight; Chief Commercial Officer; MedTech; Leadership appointment; Chris Barry; MedSurg; Dental Solutions; Health Information Systems; Global commercial operations; R&D
Geron Corporation Announces Executive Leadership Transitions and Appointments
Geron Corporation; executive leadership; appointments; departures; commercial strategy; RYTELO; Harout Semerjian; Ahmed ElNawawi; Andrew Grethlein; Jim Ziegler
GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026
GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline
Pfizer Veteran Suneet Varma Named CEO of Phase 3-Ready Biotech Startup Intent Biologics
Suneet Varma; Pfizer vet; Intent Biologics; CEO appointment; regenerative medicine; Phase 3 clinical trials; biotech startup; inflammation and immunology